Our Therapeutic Approach
A proprietary protein, delivered subcutaneously, that stimulates heart regeneration after cardiac injury
The Discovery
Inducing Cardiac Regeneration in Humans
The devastating impact of myocardial infarction is a result of the inability of the adult human heart to regenerate after injury. Cells in some other tissues, such as skin and bone, will proliferate to rebuild damaged tissue. In the heart, however, once damage occurs, it is permanent...until now.
The founders of Regencor have discovered a protein, REG101, that can promote cardiac regeneration. This proprietary protein can drive human cardiac muscle proliferation in vitro, and heart regeneration in adult mammals after myocardial infarction.
The regenerative protein safely promotes:
New cardiac muscle growth
New myocardial blood vessel formation
Significant scar reduction
Significant recovery of cardiac function
The unique elements of Regencor’s therapeutic approach:
Potential to cure heart failure
Our recombinant protein reverses tissue damage, restores cardiac function, and prevents progression to heart failure after MI.
Candidate for accelerated FDA approval
Likely designated as regenerative medicine advanced therapy.
Simple critical path for development
Does not utilize complex biologicals that must be delivered by injected vectors or cells.
Straightforward clinical implementation
Outpatient subcutaneous administration.
Deep market penetration
Our formulation is designed for use in both the acute MI & the chronic heart failure markets.
Established proof of safety & efficay
Demonstrated in both small and large animal studies.